AbbVie: Ibrutinib inhibited pre-germinal center B cells in trial
AbbVie announced new data on the biologic and cellular mechanisms of IMBRUVICA in patients with chronic graft-versus-host disease a potentially life-threatening consequence of an allogeneic stem cell or bone marrow transplant. New results showed ibrutinib selectively inhibited pre-germinal center B cells and follicular helper T cells that are believed to play a critical role in treating cGVHD. In addition, the data also showed that ibrutinib preserved immune memory and Th1 T cells, which suggests the potential for additional treatment benefit. These results were observed in a Phase 1b/2 trial. The data will be presented at the 59th American Society of Hematology Annual Meeting and Exposition on Dec. 11 in Atlanta IMBRUVICA is a first-in-class Bruton's tyrosine kinase inhibitor jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc. "These new data further underscore the potential benefit of IMBRUVICA in chronic graft-versus-host disease, and provide encouraging signs for its mechanism of action in a way that's meaningful to advancing treatment," said Lori Styles, M.D., Senior Medical Director and GVHD program clinical lead at Pharmacyclics LLC, an AbbVie company.